// App-Quantinova.ai

: Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients (pts) with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)-Rearrangement or Nucleophosmin 1 (NPM1) Mutation

Researchers

Presenter

  • Naval Daver

Principal Investigators

  • John Affinito

  • Hongliang Cai

  • Hanna Dobrowolska

  • Edward Dow

  • Ken Eguchi

  • Gregory Song

  • Jay Stoudemire

  • Akinobu Watanbe

  • Philip Komarnitsky

Medical Centers

  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • United States

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

  • Genetic Disorder

Disease

  • Acute lymphoblastic leukemia

  • Acute myelocytic leukemia

  • Acute Leukemia

Biomarkers

  • Nucleophosmin 1

  • Breakpoint Cluster Region

  • Histone-lysine N-methyltransferase 2A

  • Cytochrome P450 Family 3 Subfamily A Member 4

Drug/Treatment

  • Itraconazole

  • Canadiol

  • Ketoconazole

  • Fuldazin

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

  • Open Label

  • Multiple Ascending Dose

  • Single Arm

  • Expansion Study

  • Dose Escalation

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved